Clinical Trial

DM Treatment to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone in Patients with Type 2 Diabetes

Study acronym: KLIMT
Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated March 17, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Key finding of DM Treatment with combination, A MuLticenter, Randomized, Parallel, Gathering Information of phase 4 Trial to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone add-on to Metformin and DPP-4 inhibitor in Patients with Type 2 Diabetes Who Have Inadequate Glycaemic Control on a Background Combination of Metformin and DPP-4 inhibitor(KLIMT Study)
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-10.
Trial Details
NCT Number NCT06875193
Lead Sponsor Dong Wha Pharmaceutical Co. Ltd.
Conditions Type2diabetes
Enrollment 196 participants
Start Date 2024-05-28
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-03-17